Evoke Receivables Turnover from 2010 to 2024

EVOK Stock  USD 4.31  0.10  2.38%   
Evoke Pharma Receivables Turnover yearly trend continues to be quite stable with very little volatility. Receivables Turnover may rise above 8.08 this year. From the period between 2010 and 2024, Evoke Pharma, Receivables Turnover regression line of its data series had standard deviation of  2.60 and standard deviation of  2.60. View All Fundamentals
 
Receivables Turnover  
First Reported
2010-12-31
Previous Quarter
7.69700373
Current Value
8.08
Quarterly Volatility
2.59627051
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Evoke Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evoke Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 131.7 K, Interest Expense of 603.8 K or Selling General Administrative of 11.6 M, as well as many indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 45.05. Evoke financial statements analysis is a perfect complement when working with Evoke Pharma Valuation or Volatility modules.
  
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

Latest Evoke Pharma's Receivables Turnover Growth Pattern

Below is the plot of the Receivables Turnover of Evoke Pharma over the last few years. It is Evoke Pharma's Receivables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evoke Pharma's overall financial position and show how it may be relating to other accounts over time.
Receivables Turnover10 Years Trend
Slightly volatile
   Receivables Turnover   
       Timeline  

Evoke Receivables Turnover Regression Statistics

Arithmetic Mean2.41
Geometric Mean1.60
Coefficient Of Variation107.77
Mean Deviation2.08
Median0.99
Standard Deviation2.60
Sample Variance6.74
Range7.0925
R-Value0.76
Mean Square Error3.10
R-Squared0.57
Significance0
Slope0.44
Total Sum of Squares94.37

Evoke Receivables Turnover History

2024 8.08
2023 7.7
2022 4.01
2021 5.48

About Evoke Pharma Financial Statements

Evoke Pharma investors utilize fundamental indicators, such as Receivables Turnover, to predict how Evoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Receivables Turnover 7.70  8.08 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.37)
Revenue Per Share
7.792
Quarterly Revenue Growth
0.698
Return On Assets
(0.34)
Return On Equity
(3.50)
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.